Haesook Teresa Kim

The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD.

DeFilipp Z, Kim HT, Spyrou N, Katsivelos N, Kowalyk S, Eng G, Kasikis S, Beheshti R, Baez J, Akahoshi Y, Ayuk F, Choe H, Etra A, Grupp SA, Hexner EO, Hogan WJ, Kitko CL, Qayed M, Reshef R, Vasova I, Zeiser R, Young R, Holler E, Ferrara JLM, Nakamura R, Levine JE, Chen YB.

Blood Adv. 2024 Jul 09. 8(13):3488-3496. PMID: 38640197

Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia.

Koury LCA, Kim HT, Undurraga MS, Navarro-Cabrera JR, Salinas V, Muxi P, Melo RAM, Gloria ABF, Pagnano KBB, Nunes EC, Bittencourt RI, Rojas N, Quintana Truyenque SM, Ayala-Lugo AI, Oliver AC, de Figueiredo-Pontes LL, Traina F, Moreira F, Fagundes EM, Duarte BKL, Mora-Alferez AP, Ortiz P, Untama JL, Tallman MS, Ribeiro RC, Ganser A, Dillon RJ, Valk PJM, Sanz MA, Löwenberg B, Berliner N, Rego EM.

Blood. 2024 May 28. PMID: 38805638

Active infection at the time of CD34+ selected stem cell boost is associated with treatment failure and poor survival.

Shapiro RM, Kim HT, Dulery R, Liney D, Garrity HM, Panaro KM, Au C, Gervais C, Little JS, Ho VT, Cutler CS, Koreth J, Gooptu M, Antin JH, Kelkar AH, Romee R, Wu CJ, Ritz J, Soiffer RJ, Nikiforow S.

Blood Adv. 2024 May 15. PMID: 38748871

Third-party fecal microbiota transplantation for high-risk treatment-naïve acute GVHD of the lower GI tract.

DeFilipp Z, Damania AV, Kim HT, Chang CC, El-Jawahri A, McAfee SL, Bottoms AS, Toncheva V, Smith MM, Dolaher M, Perry L, White M, Diana B, Connolly S, Dey BR, Frigault MJ, Newcomb RA, O'Donnell PV, Spitzer TR, Mansour MK, Weber D, Ajami NJ, Hohmann E, Jenq RR, Chen YB.

Blood Adv. 2024 May 14. 8(9):2074-2084. PMID: 38471063

Comparison of Older Related versus Younger Unrelated Donors for Older Recipients of Allogeneic Hematopoietic Cell Transplantation with Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Large Single-Center Analysis.

Kim HT, Ho VT, Nikiforow S, Cutler C, Koreth J, Shapiro RM, Gooptu M, Romee R, Wu CJ, Antin JH, Ritz J, Soiffer RJ.

Transplant Cell Ther. 2024 Jul. 30(7):687.e1-687.e13. PMID: 38703824

Competing risks data in clinical oncology.

Kim HT.

Front Oncol. 2024. 14:1360266. PMID: 38638853

A Clinicopathological Appraisal of Duodenal Neuroendocrine Tumors at a Racially Diverse Safety Net Hospital.

Shaikh SD, Jacoba I, Sun N, Chung E, Kim HT, Zhao Q, Weber HC.

Am J Gastroenterol. 2024 Mar 20. PMID: 38345246

Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML.

Cutler CS, Gooptu M, Ho VT, Koreth J, Nikiforow S, Romee R, Shapiro R, DeAngelo DJ, Stone RM, Bat-Erdene D, Ryan J, Contreras ME, Fell G, Letai A, Ritz J, Lindsley RC, Soiffer RJ, Antin JH, Garcia JS, Kim HT, Murdock HM, Ansuinelli M, Brock J.

Blood Adv. 2024 Feb 27. 8(4):978-990. PMID: 38197938

Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease.

Wobma H, Kapadia M, Kim HT, Alvarez-Calderon F, Baumeister SHC, Duncan C, Forrest S, Gorfinkel L, Huang J, Lehmann LE, Li H, Schwartz M, Koreth J, Ritz J, Kean LS, Whangbo JS.

Blood Adv. 2023 08 22. 7(16):4647-4657. PMID: 37603347

Posttransplant cyclophosphamide vs tacrolimus-based GVHD prophylaxis: lower incidence of relapse and chronic GVHD.

Maurer K, Ho VT, Inyang E, Cutler C, Koreth J, Shapiro RM, Gooptu M, Romee R, Nikiforow S, Antin JH, Wu CJ, Ritz J, Soiffer RJ, Kim HT.

Blood Adv. 2023 08 08. 7(15):3903-3915. PMID: 37156098